Coinbase
COIN
Microsoft
MSFT
Apple
AAPL
Meta Platforms
META
MARA Holdings
MARA
US Stock MarketDetailed Quotes
NMRA Neumora Therapeutics
- 10.250
- -0.270-2.57%
Trading Dec 12 10:33 ET
1.66BMarket Cap9.23P/E (TTM)
10.475High10.130Low145.68KVolume10.460Open10.520Pre Close1.50MTurnover0.17%Turnover RatioLossP/E (Static)161.56MShares21.00052wk High5.16P/B870.43MFloat Cap8.33052wk Low--Dividend TTM84.92MShs Float21.000Historical High--Div YieldTTM3.28%Amplitude8.330Historical Low10.310Avg Price1Lot Size
About Neumora Therapeutics Company
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.
Company Profile
SymbolNMRA
Company NameNeumora Therapeutics
Listing DateSep 15, 2023
Issue Price17.00
Founded2019
CEOMr. Henry O. Gosebruch
MarketNASDAQ
Employees124
Fiscal Year Ends12-31
Address490 Arsenal Way,Suite 200
CityWatertown
ProvinceMassachusetts
CountryUnited States of America
Zip Code02472
Websitehttp://www.neumoratx.com
Company Executives
- Name
- Position
- Salary
- Henry O. Gosebruch
- Director, President and Chief Executive Officer
- 22.00M
- Dr. Joshua Pinto, PhD
- Chief Financial Officer
- --
- Carol Suh
- Chief Operating Officer
- --
- Dr. Daljit Singh Aurora, Pharm.D.
- Chief Strategy Officer
- --
- Jason G. Duncan
- Chief Legal Officer
- 4.12M
- Michael Lee Milligan
- Principal Accounting Officer
- --
- Paul L. Berns
- Executive Chairman of the Board
- 8.57M
- Matthew K. Fust
- Independent Director
- 485.53K
- David Piacquad
- Independent Director
- 620.76K
- Alaa Halawa
- Independent Director
- 671.20K
- Kristina M. Burow
- Independent Director
- 686.60K
- Dr. Maykin Ho, PhD
- Independent Director
- 430.97K
- Dr. Robert Lenz, M.D.
- Head of Research and Development
- 13.58M
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.